Education
About Us
Working with TipRanks
Follow Us
Celldex Therapeutics Inc (CLDX)
NASDAQ:CLDX
CLDX Analyst Ratings
Strong Buy
9 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CLDX Stock 12 Month Forecast
Average Price Target
$63.22
▲(300.63% Upside)
| Highest Price Target$90.00 | Average Price Target$63.22 | Lowest Price Target$36.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Morgan Stanley
Initiated
03/20/25
H.C. Wainwright
Reiterated
03/03/25
Leerink Partners
Reiterated
03/02/25
Goldman Sachs
Reiterated
02/28/25
Stifel Nicolaus
Reiterated
02/28/25
TD Cowen
Reiterated
02/27/25
Cantor Fitzgerald
Reiterated
01/29/25
Guggenheim
$90
Buy
470.34%
Upside
Reiterated
01/08/25
Guggenheim on Celldex Therapeutics (CLDX): CLDX Remains Leader In The Mast Cell SpaceGuggenheim analyst Yatin Suneja reiterated a Buy rating and $90.00 price target on Celldex Therapeutics (NASDAQ: CLDX)
Citi
$70
Buy
343.60%
Upside
Reiterated
01/08/25
Buy Rating for Celldex: Strategic Market Position and Growth Potential Amid Jasper's Delayed Competition
Wells Fargo
$44
Buy
178.83%
Upside
Reiterated
11/06/24
Celldex's Promising Pipeline and Undervaluation Justify Buy Rating
LifeSci Capital
$74
Buy
368.95%
Upside
Reiterated
10/28/24
Celldex's Promising Phase 2 Results and Strong Financial Position Warrant a Buy Rating
Wolfe Research
$51
Hold
223.19%
Upside
Downgraded
09/26/24
Celldex barzolvolimab data above expectations, says Wolfe ResearchCelldex barzolvolimab data above expectations, says Wolfe Research
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
Initiated
03/20/25
H.C. Wainwright
Reiterated
03/03/25
Leerink Partners
Reiterated
03/02/25
Goldman Sachs
Reiterated
02/28/25
Stifel Nicolaus
Reiterated
02/28/25
TD Cowen
Reiterated
02/27/25
Cantor Fitzgerald
Reiterated
01/29/25
Guggenheim
$90
Buy
470.34%
Upside
Reiterated
01/08/25
Guggenheim on Celldex Therapeutics (CLDX): CLDX Remains Leader In The Mast Cell SpaceGuggenheim analyst Yatin Suneja reiterated a Buy rating and $90.00 price target on Celldex Therapeutics (NASDAQ: CLDX)
Citi
$70
Buy
343.60%
Upside
Reiterated
01/08/25
Buy Rating for Celldex: Strategic Market Position and Growth Potential Amid Jasper's Delayed Competition
Wells Fargo
$44
Buy
178.83%
Upside
Reiterated
11/06/24
Celldex's Promising Pipeline and Undervaluation Justify Buy Rating
LifeSci Capital
$74
Buy
368.95%
Upside
Reiterated
10/28/24
Celldex's Promising Phase 2 Results and Strong Financial Position Warrant a Buy Rating
Wolfe Research
$51
Hold
223.19%
Upside
Downgraded
09/26/24
Celldex barzolvolimab data above expectations, says Wolfe ResearchCelldex barzolvolimab data above expectations, says Wolfe Research
Best Analysts Covering Celldex
Which Analyst Should I Follow If I Want to Buy CLDX and Sell After:
1 Month
xxx
Success Rate
12/22 ratings generated profit
Average Return
+5.80%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +5.80% per trade.
3 Months
xxx
Success Rate
11/22 ratings generated profit
Average Return
+11.64%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +11.64% per trade.
1 Year
Success Rate
8/15 ratings generated profit
Average Return
+84.03%
reiterated a buy rating 2 months ago
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +84.03% per trade.
2 Years
xxx
Success Rate
6/15 ratings generated profit
Average Return
+54.08%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of +54.08% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CLDX Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
17
13
11
8
9
Buy
4
1
2
3
3
Hold
3
1
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
15
13
12
13
Each month's total comprises the sum of three months' worth of ratings.
CLDX Financial Forecast
CLDX Stock Forecast FAQ
What is CLDX’s average 12-month price target, according to analysts?
Based on analyst ratings, Celldex Therapeutics Inc’s 12-month average price target is $63.22.
What is CLDX’s upside potential, based on the analysts’ average price target?
Celldex Therapeutics Inc has 300.63% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CLDX a Buy, Sell or Hold?
Celldex Therapeutics Inc has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
What is Celldex Therapeutics Inc’s price target?
The average price target for Celldex Therapeutics Inc is $63.22. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $90.00 ,the lowest forecast is $36.00. The average price target represents 300.63% Increase from the current price of $15.78.
The highest analyst price target is $90.00 ,the lowest forecast is $36.00. The average price target represents 300.63% Increase from the current price of $15.78.
What do analysts say about Celldex Therapeutics Inc?
Celldex Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of CLDX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.